Saturday, May 25, 2013 Last update: Yesterday, 10:04 PM
Company Tech News as it Breaks
Cognoptix
News articles for Cognoptix:
Wednesday, May 22, 2013
- Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in Proof-of-Concept Clinical TrialCognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid ... read more
Tuesday, April 9, 2013
- Cognoptix reaches halfway point of pre-pivotal clinical trial of drug/device test designed to identify Alzheimer’s disease via beta amyloid signature in the eyesCognoptix announced today that it has reached the halfway point in a multi-site clinical trial of its SAPPHIRE II eye test designed to ... read more
Thursday, February 28, 2013
- Cognoptix begins pre-pivotal clinical trial of its drug/device test designed to identify Alzheimer’s disease via beta amyloid signature in the eyesCognoptix announced today that it has begun a 40-patient clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer’s disease patients via a beta ... read more
Thursday, January 3, 2013
- Cognoptix Drug/Device Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in a 10-Subject Proof-of-Concept Clinical TrialCognoptix, an emerging medical device company announced today that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid ... read more
Tuesday, December 4, 2012
- Cognoptix Exclusively Licenses Alzheimer’s-Detection Technology from the University of California at San Diego: Color-Coded Markers of Beta Amyloid That Empower Doctors to Diagnose Alzheimer’s and OthCognoptix, an emerging medical device company previously known as Neuroptix, announced today that it has exclusively licensed groundbreaking technology from the University of California at San Diego ... read more